Introduction
Primary cilia, found at the surface of many cells, are sensory organelles known to perceive protein‐mediated (e.g. Hedgehog) and mechanical signals (e.g. fluid flow). Defects in ciliary function lead to a number of human diseases, termed ciliopathies. Ciliopathies can affect the kidney, where mutations that lead to disruption of ciliary form or function result in polycystic kidney disease (PKD). For example, autosomal dominant and recessive PKD (ADPKD and ARPKD), and nephronopthisis, are ciliopathies caused by mutations in genes encoding the ciliary proteins polycystin‐1 (Consortium ; Hughes et al. ; Yoder et al. ) (PC‐1, ADPKD), PC‐2 (Mochizuki et al. ; Yoder et al. ; Boletta and Germino ) (ADPKD), fibrocystin (Zerres et al. ; Onuchic et al. ; Ward et al. , ) (ARPKD), and the nephrocystins (nephronophthisis) (Jauregui ; Hurd and Hildebrandt ). The cystic overgrowth characteristic of PKD ultimately leads to the destruction of kidney architecture and renal failure (Grantham ). Although PKD accounts for ~5% of all cases of end‐stage kidney disease (ESKD) (Kc and Ly ; Ibraghimov‐Beskrovnaya and Bukanov ) in the United States and, thus presents a significant burden, the molecular mechanisms linking ciliary mutations to the cystic phenotype remain unclear. Given that supportive care is the only “treatment” currently approved for any form of PKD, a better understanding of ciliary biology is essential to develop much‐needed new therapies for PKD. Here, we examine a novel signaling mechanism that links renal primary cilia to exosomes and the exocyst complex.
Exosomes are small, membrane‐bound vesicles that are released into the extracellular environment (Mathivanan et al. ). Exosomes can mediate cell–cell communication and affect signal transduction in recipient cells in both normal and pathological conditions (Calzolari et al. ; Admyre et al. ; Mallegol et al. ; Masyuk et al. ; Lee et al. ; Li et al. ). For example, platelet‐derived exosomes regulate coating events (Cocucci et al. ); exosomes from intestinal epithelia activate the mucosal system (Mallegol et al. ); while tumor‐derived exosomes transfer oncogenic receptors to receiving cells (Al‐Nedawi et al. ). In the kidney, and other organs, exosomes have been suggested to carry disease‐specific biomarkers (e.g. for acute kidney injury, chronic kidney disease, podocyte injury, cancers, and PKD (Pisitkun et al. ; Cheruvanky et al. ; Camici ; D'Souza‐Schorey and Clancy )). Lending credence to this idea, a very recent study showed that specific C. elegans ciliated sensory neurons shed and release exosome‐sized extracellular vesicles containing GFP‐tagged polycystins LOV‐1, the PKD‐1 C. elegans ortholog (Barr and Sternberg ), and PKD‐2 and that these extracellular vesicles were abundant in the lumen surrounding the cilium (Wang et al. ). Furthermore, EM and genetic analysis indicated that the extracellular vesicle biogenesis occurred via budding from the plasma membrane at the ciliary base, and not via fusion of multivesicular bodies, and that intraflagellar transport and kinesin‐3 KLP‐6 were required for environmental release of PKD‐2::GFP‐containing extracellular vesicles. Finally, extracellular vesicles isolated from wild‐type animals induced male tail‐chasing behavior, while extracellular vesicles isolated from klp‐6 animals and lacking PKD‐2::GFP did not, indicating that environmentally released extracellular vesicles play a role in animal communication and mating‐related behaviors (Wang et al. ). Given the growing evidence of the existence and biological importance of these cilia‐interacting vesicles, the question of how they're regulated within the cell arises. We hypothesize that the exocyst complex plays a critical role in regulating these vesicles.
The exocyst complex (a.k.a. the exocyst) is a ~750 kDa octameric protein complex initially identified in S. cerevisiae and highly conserved from yeast to mammals (Novick et al. ; Hsu et al. ). The mammalian exocyst comprises Exoc1/Sec3, Exoc2/Sec5, Exoc3/Sec6, Exoc4/Sec8, Exoc5/Sec10, Exoc6/Sec15, Exoc7/Exo70, and Exoc8/Exo84 (Novick et al. ; Hsu et al. ) and is best known for its role in targeting and docking vesicles carrying membrane proteins from the trans‐Golgi network (TGN) (Lipschutz and Mostov ). Importantly, we previously showed, in renal tubule cells, that exocyst components are localized to primary cilia (Rogers et al. ), that the exocyst is required for ciliogenesis (Zuo et al. ), and that the exocyst genetically interacts with polycystin‐2 in zebrafish (Fogelgren et al. ; Choi et al. ). Mutations in an exocyst component were also recently shown to cause PKD in a human family with Joubert Syndrome, a nephronophthisis form of PKD (Dixon‐Salazar et al. ). Thus, a link between the exocyst complex, primary cilia, and cystic kidney disease, has been established. We have also shown, via electron microscopy (EM) (Hogan et al. ; Bakeberg et al. ), that cilia appear to interact with exosomes. Exosome‐like vesicles (ELVs) are a subset of exosomes that carry cilia‐specific membrane proteins, including various proteins involved in polycystic kidney disease, such as PC‐2, as well as other ciliary membrane proteins, such as Smoothened (Smo) (Hogan et al. ; Bakeberg et al. ).
Given that understanding the mechanisms that mediate cilia/ELV interactions could be critical for understanding the biology that links cilia to renal pathogenesis, particularly to different forms of PKD, we decided to further explore a possible link between renal primary cilia, urinary ELVs, and the exocyst complex. Here, we show via transmission electron microscopy (TEM) with immunogold labeling that the exocyst complex localizes to both primary cilia in renal epithelial cells, and to membrane‐vesicles that interact with primary cilia. We further confirm this finding by showing that every member of the exocyst complex, as well as most of its known regulatory GTPases, is present in purified human urinary ELVs. Lastly, we expand on previous EM work to show that exosomes appear to interact with primary cilia in renal cells. Taken together, these data support the idea of a functional/physical link exists between primary cilia, ELVs, and the exocyst complex. Furthermore, given the previously established relationship between cilia, the exocyst complex, and renal cystogenesis, we hypothesize that not only is the exocyst complex at the right place to mediate cilary/ELV interactions, but that these processes play a central role in the biology of PKD.
Materials and Methods
Cell culture
Type II Madin–Darby canine kidney (MDCK) cells were used between passages 3 and 10. These cells were originally cloned by Dr. D. Louvard (European Molecular Biology Laboratory, Heidelberg, Germany) and came to us via Dr. Mostov who obtained them from Dr. K. Matlin (University of Chicago, Chicago, IL). We previously generated MDCK type II cells overexpressing myc‐tagged‐hSec10 (Lipschutz et al. ). MDCK type II cells overexpressing Smoothened‐YFP were generously provided to us by Drs. Ott and Lippincott‐Schwartz (Ott et al. ). Cells were cultured in modified Eagle's minimal essential medium containing Earl's balanced salt solution and glutamine supplemented with 5% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. MDCK cells were seeded at confluence on 24‐mm Transwell filter units coated with collagen (Corning Life Sciences, Lowell, MA). Cell monolayers were used for experiments after 7–14 days of culture with daily changes in medium.
Transmission electron microscopy
MDCK cells were grown on Transwell filters for 7 days and subsequently fixed in a solution containing 2% glutaraldehyde, 0.8% paraformaldehyde, and 0.1 M cacodylate. Cells were stained with osmium and imidazole as described previously (Lipschutz et al. ). Briefly, cells were dehydrated, embedded in resin, and sectioned. Immunolabeling was performed using mouse anti‐myc antibody (mouse monoclonal anti‐myc, #2276 Cell Signaling, at 1:200 dilution) to identify the myc epitope present on Sec10. Secondary goat anti‐mouse antibody (Jackson ImmunoResearch, West Grove, PA) was tagged with ultrasmall gold (Aurion, Immuno Gold Reagents & Accessories, Wageningen, the Netherlands). The gold label was further enhanced with silver staining for 25 minutes. Finally, the cells were imaged on a FEI Tecnai transmission electron microscope (JEOL 1010) fitted with a Hamamatsu digital camera and imaging software from Advanced Microscopy Techniques, Danvers, MA.
Spinning disk confocal microscopy
Smoothened‐YFP MDCK cells were grown upside‐down on Transwell filters for 7 days. To accomplish this, Smoothened‐YFP MDCK cells were seeded on the bottom of inverted Transwell filters, allowed to attach, and the Transwell filters were then placed in the normal upright position for 7 days. For imaging, Transwell filters, containing the cells growing on the bottom of the filters, were placed on glass‐bottom cultured plates with the apical cell surface (where the cilia are located) touching the glass. This allowed for optimal imaging. Cells were imaged at the University of Pennsylvania CDB microscopy Core using an Olympus IX71 spinning disk confocal microscope fitted with a Hamamatsu ImagEM EMCCD camera and Metamorph imaging software. Images were processed in Fiji (Image J) Software to add scale bar and time stamps, and to generate the time‐lapse illustrations of ELV/cilia interactions. The labels and arrows were added to the time‐lapse panels in Adobe Photoshop.
Isolation of human urinary ELVs and mass spectrometry analysis
Urinary ELVs were isolated following a modification of the methods of Pisitkun et al. () and Zhou et al. () as previously described (Hogan et al. ; Chen et al. ). Briefly, the first void of the day was collected and treated with one tablet of Complete Protease Inhibitor, EDTA‐free (Roche, New York, NY) to continuously inhibit serine and cysteine proteases. If the samples were not to be used immediately, the urine was frozen at −80°C, and then vigorously vortexed during thawing when it was ready to be used. To pellet cellular debris, the samples were subsequently centrifuged at room temperature in a Sorvall Revolution RC centrifuge 4,275‐rpm (4,000 × g) using at SLC‐600 rotor. The supernatant was then filtered using an 80‐μm nylon mesh filter to prevent the carryover of any pelleted material into subsequent centrifugation steps. The filtered supernatant was subsequently centrifuged at 45,000 rpm (225,000 × g) for 2 h at 4°C in a Sorvall Discovery 90SE ultracentrifuge to generate a “crude ELV” fraction containing Tamm–Horsfall protein (THP) and a few ELVs. To remove THP, crude ELV fractions were layered on top of a 5–30% sucrose gradient with heavy water (D2O). The gradient was centrifuged at 200,000 × g for 24 h, and then the fractions were harvested, diluted five‐ to 10‐fold in PBS and centrifuged at 150,000 × g for 1 h to recover PKD‐ELVs. These were stored in 100 μL of 0.25 M Sucrose 20 mM HEPES (pH 6.0) with 1× Complete Protease Inhibitor and frozen down at −80°C if they were not immediately used. Purified ELV fractions were run on MOPS gels in normal water, stained and destained, and digested with trypsin again in normal water, diluting residual D2O to background levels before proteomic analysis, and reversing any potential exchange reactions. The total time exposed to normal water was at least 5 days. Subsequently, PKD‐ELV fractions were subjected to mass spectrometry analysis to identify proteins present in ELVs (Hogan et al. ; Chen et al. ).
Proteomics analysis of the exocyst
We searched our ELV proteome for the exocyst complex as well as GTPases using Scaffold Software (Proteome Software, Inc., Portland, OR). All members of the exocyst complex were quickly identified using the search term “EXOC”. To identity GTPases in the ELV proteome, we used the following search terms “Arf”, “Arl”, “Cdc”, “GTP”, “Rab”, “Rac”, “Ral”, “Ras” and “Rho”. Lists containing any of these terms were exported to Microsoft Excel where duplicate results were removed. Known GTPases within this group, were identified using functional cluster analysis on DAVID Bioinformatics Resources 6.7 (Huang et al. ) yielding over 100 potential GPTase or GTPase regulatory proteins present in ELVs.
To determine which, if any, of these proteins were previously known to interact with the exocyst, a gene interaction network was established by searching Biogrid 3.2 (a literature‐curated database of protein and genetic interactions,
Human participants
As previously reported (Hogan et al. ), urine samples were obtained from normal human volunteers. This study was performed in adherence to the Declaration of Helsinki and approved by the Mayo Clinic IRB:09003355: “Analysis of the proteome of PKD‐ELVs in polycystic kidney disease and controls”.
Results
The exocyst localizes to primary cilia and cilia‐interacting vesicles
To determine the localization of the exocyst complex, we used MDCK cells that stably express myc‐tagged‐human Sec10 (hSec10‐myc cells) (Lipschutz et al. ). To visualize the intracellular localization of hSec10, Transwell filter‐grown hSec10‐myc MDCK‐II cells were fixed and subjected to transmission electron microscopy (TEM). Since an anti‐hSec10‐antibody suitable for EM was not available, we used a mouse anti‐myc monoclonal antibody, and a silver enhanced gold secondary antibody to visualize myc‐tagged hSec10 (Zuo et al. ). Here, we confirm that the exocyst component Sec10 is localized to renal primary cilia in MDCK cells (Fig. ). Moreover, we show that in addition to being present at the base of the primary cilium, where it would be expected, based on the known role of the exocyst in vesicle trafficking, exocyst Sec10 was found all along the primary cilium, and in what appear to be membrane bound vesicles interacting with the primary cilium (Fig. , insets). Given that Sec10 is an essential member of the exocyst complex (Zuo et al. ), these data suggest that the exocyst is present in membrane vesicles that interact with primary cilia.
The exocyst is present in cilia‐interacting exosome‐like vesicles (ELVs)
To determine whether the exocyst complex is found in ELVs, we purified secreted vesicles from human urine. Briefly, human urine was subjected to ultracentrifugation to generate a crude exocyst preparation, which was subsequently fractionated using a D2O sucrose gradient to generate a fraction enriched for a subset of exosomes that carry cilia‐specific proteins such as polycystin‐2, which we have previously named exosome‐like vesicles or ELVs (Hogan et al. ). ELV‐rich fractions were subjected to mass‐spectrometry‐based proteomic analysis to identify ELV cargo as previously described (Hogan et al. ). Supporting our findings from TEM, analysis of human urinary exosomes shows that all eight members of the exocyst complex are found in urinary ELVs (Fig. ). This proteomic analysis shows multiple unique peptides identified for each protein (highlighted for each protein) covering from 20% to more than 50% for each of the eight component proteins of the exocyst complex. Importantly, all eight members of the mammalian exocyst complex were present in the ELVs suggesting that the entire complex, and not just individual exocyst proteins, have a function in ELV biology.
Small GTPases that regulate the Exocyst are present in ELVs
To determine if the exocyst was just a “bystander” or has a more functional role in ELVs, we searched for GTPases that have been shown to regulate the exocyst. We found that, among many other GTPases, GEFs and GAPS, ELVs carry nine small GTPases known to physically interact with and/or regulate the exocyst (Fig. , Table ), including: ARF6, which interacts with Exoc5/Sec10 (Prigent et al. ); RAL A, which interacts with Exoc2/Sec5 and Exoc8/Exo84 (Formstecher et al. ), RAL B which interacts with Exoc2/Sec5 and Exoc8/Exo84 (Moskalenko et al. ); RHOQ, which interacts with Exoc7/Sec15 (Inoue et al. ); RAN/GSP1, which interacts with Exoc1/Sec3 (Braunwarth et al. ), RHOA/RHO1 which interacts with Exoc1/Sec3 (Guo et al. ; Zhang et al. ; Yamashita et al. ); RAB8/SEC4 which interacts with Exoc1/Sec3 (Finger et al. ) and EXOC6/Sec15 (Bowser et al. ; Guo et al. ; Heger et al. ), RAP1B/Bud1 which interacts with Exoc6/Sec15 (Drees et al. ); and CDC42, which interacts with Exoc1/Sec3 and Exoc5/Sec10 (we showed this genetically in zebrafish, as well as by co‐IP) (Zhang et al. , ; Wu and Brennwald ), and Exoc7/Exo70 (Wu and Brennwald ; Wu et al. ). Thus, ELVs contain the entire exocyst complex and most of its known regulatory GTPases.
Exocyst regulatoryEntrez ID | Name | Human Ortholog | Human Entrez ID | Present in ELVs |
382 | ARF6 | ARF6 | 382 | Yes |
5898 | RALA | RALA | 5898 | Yes |
5899 | RALB | RALB | 5899 | Yes |
23433 | RHOQ | RHOQ | 23433 | Yes |
856294 | RHO1 | RHOA | 387 | Yes |
850930 | CDC42 | CDC42 | 998 | Yes |
851000 | GSP1p | RAN | 5901 | Yes |
853056 | RSR1 | RAP1B | 5908 | Yes |
Small, fluorescently tagged membrane‐vesicles appear to interact with cilia in MDCK cells
To further examine a possible interaction between exosomes and the primary cilium, we used MDCK cells that express fluorescently tagged ciliary membrane protein Smoothened (Smoothened‐YFP/SmoYFP) (Ott et al. ), which is found in ELVs, and spinning disk and TIRF microscopy. We identified small vesicles that appear to interact with renal epithelial tubule cell primary cilia (Fig. A and Movie S1). However, given the fact that the size of the exosomes is very close to (or below) the resolution limits of light microscopy, further work will be required to capture these potential interactions at greater resolution, and to determine the functional roles of these processes in different cells.
ELVs carry proteins known to interact with Smoothened, Polycystins 1 and 2 and Fibrocystin
We found that ELVs carry three out of 14 first‐neighbors/first‐degree Smoothened interactors (Fig. B). As described in Table , these are RPS21, which physically interacts with Smoothened; and PAFAH1B3 and SNRPD2, which are known to genetically interact with Smoothened.
Smoothened interactors in human urinarySymbol | Protein name | Uniprot ID | Interaction type | Present in ELVs |
TCF21 | Transcription Factor 21 | O43680 | Genetic | No |
RAD17 | RAD 17 homolog | O75943 | Genetic | No |
FAM155B | Family with sequence similarity 155, member B | O75949 | Physical | No |
RPS21 | Ribosomal protein S21 | P08865 | Physical | Yes |
SNRPD2 | Small nuclear ribonucleoprotein D2 | P62316 | Genetic | Yes |
PTCH1 | Patched 1 | Q13635 | Physical | No |
PAFAH1B3 | Platelet‐activating factor acetylhydrolase 1b | Q15102 | Genetic | Yes |
OR10T2 | Olfactory receptor, family 10, subfamily T, member 2 | Q8NGX3 | Genetic | No |
PNPLA2 | Patatin‐like phospholipase domain containing 2 | Q96AD5 | Genetic | No |
DYNLL2 | Dynein, light chain, LC8‐type2 | Q96FJ2 | Physical | No |
SMO | Smoothened | Q99835 | Yes | |
KRTAP4‐4 | Keratin associated protein 4‐4 | Q9BYR3 | Genetic | No |
ZNF226 | Zinc finger protein 226 | Q9NYT6 | Genetic | No |
PSG8 | Pregnancy specific beta‐1‐glycoprotein 8 | Q9UQ74 | Genetic | No |
PTCH2 | Patched 2 | Q9Y6C5 | Physical | No |
2Queried protein: “Queried protein” refers to the protein for which we searched the database for known interacting proteins that are found in ELVs.
Likewise, ELVs also carry proteins that interact with Polycystins 1 and 2 and Fibrocystin in a first‐degree basis (Fig. C). As illustrated in Fig. C, we found six out of 11 Polycystin‐1 interactors, six out of 13 polycystin‐2 interactors, and two out of seven Fibrocystin interactors in human urinary ELVs (Table ). The Polycystin‐1 interactors were as follows: talin‐1 (TLN1); Polycystin‐2 (PKD‐2), beta catenin (CTNNB1); keratin‐18 (KRT‐18); fibronectin (FN1); and the alpha I chain of collagen (COL1A). Notably, all of these proteins are known to physically interact with Polycystin‐1 (Table ). The Polycystin‐2 interactors were as follows: tropomyosin‐1 (TPM1); phosphofurin acidic cluster sorting protein 1 (PACS1); Fibrocystin (PKHD1); protein diaphanous homolog 1 (DIAPH1); cyclin‐dependent kinase 16 (CDK16); and fibronectin (FN1). With the exception of CDK16 and FN1, which interact genetically with PKD‐2, all of the above are known to physically interact with Polycystin‐2. Lastly, both Fibrocystin interactors identified in human urinary ELVs, namely CDK16 and FN1, genetically interact with PKHD1.
Symbol | Protein Name | Uniprot ID | Interaction Type | Interacts with | In ELVs |
TLN1 | Talin‐1 | Q9Y490 | Physical | PKD1 | Yes |
SIAH1 | E3 Ub Ligase SIAH1 (seven in absentia homolog 1) | Q8IUQ4 | Physical | PKD1 | No |
RGS7 | Regulator of G‐protein signaling 7 | P49802 | Physical | PKD1 | No |
PKD2 | Polycystin 2 | Q13563 | Physical | PKD1 | Yes |
CTNNB1 | Beta Catenin | P35222 | Physical | PKD1 | Yes |
FYN | Tyrosine‐protein kinase Fyn | P06241 | Physical | PKD1 | No |
KRT‐18 | Keratin, type I cytoskeletal 18 | P05783 | Physical | PKD1 | Yes |
FN1 | Fibronectin | P02751 | Physical | PKD1 | Yes |
COL2A1 | Collagen alpha‐1(II) chain | P02458 | Physical | PKD1 | No |
COL1A1 | Collagen alpha‐1(I) chain | P02452 | Physical | PKD1 | Yes |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Physical | PKD1 | No |
TRPC1 | Short transient receptor potential channel 1 | P48995 | Physical | PKD2 | No |
TPM1 | Tropomyosin‐1 | P09493 | Physical | PKD2 | Yes |
TPM1 | Tropomyosin‐1 | P09493 | Genetic | PKD2 | Yes |
TNNI3 | Cardiac troponin I | P19429 | Physical | PKD2 | No |
CD2AP | CD2‐associated protein | Q9Y5K6 | Physical | PKD2 | Yes |
GGA1 | ADP‐ribosylation factor‐binding protein GGA1 | Q9UJY5 | Physical | PKD2 | No |
PACS2 | Phosphofurin acidic cluster sorting protein 2 | Q86VP3 | Physical | PKD2 | No |
PACS1 | Phosphofurin acidic cluster sorting protein 1 | Q6VY07 | Physical | PKD2 | Yes |
PKHD1 | Fibrocystin | P08F94 | Physical | PKD2 | Yes |
BCAP31 | B‐cell receptor‐associated protein 31 | P51572 | Physical | PKD2 | No |
COL2A1 | Collagen alpha‐1(II) chain | P02458 | Genetic | PKD2 | No |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Genetic | PKD2 | No |
DIAPH1 | Protein diaphanous homolog 1 | O60610 | Physical | PKD2 | Yes |
TNNC2 | Troponin C, skeletal muscle | P02585 | Genetic | PKHD1 | No |
SPANXN5 | Sperm protein associated with the nucleus on the X chromosome N5 | Q5 MJ07 | Genetic | PKHD1 | No |
RGS7 | Regulator of G‐protein signaling 7 | P49802 | Genetic | PKHD1 | No |
BRAT1 | BRCA1‐associated ATM activator 1 | Q6PJG6 | Genetic | PKHD1 | No |
CDK16 | Cyclin‐dependent kinase 16 | Q00536 | Genetic | PKHD1 | Yes |
CAMLG | Calcium signal‐modulating cyclophilin ligand | P49069 | Physical | PKHD1 | No |
FN1 | Fibronectin | P02751 | Genetic | PKHD1 | Yes |
FN1 | Fibronectin | P02751 | Genetic | ABL1 | Yes |
TLN1 | Talin‐1 | Q9Y490 | Genetic | CD2AP | Yes |
FYN | Tyrosine‐protein kinase Fyn | P06241 | Physical | CD2AP | No |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Physical | CD2AP | No |
TPM1 | Tropomyosin‐1 | P09493 | Genetic | COL1A1 | Yes |
FN1 | Fibronectin | P02751 | Physical | COL1A1 | Yes |
FYN | Tyrosine‐protein kinase Fyn | P06241 | Genetic | COL2A1 | No |
FN1 | Fibronectin | P02751 | Physical | COL2A1 | Yes |
TPM1 | Tropomyosin‐1 | P09493 | Genetic | CTNNB1 | Yes |
FYN | Tyrosine‐protein kinase Fyn | P06241 | Physical | CTNNB1 | No |
FN1 | Fibronectin | P02751 | Genetic | CTNNB1 | Yes |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Physical | CTNNB1 | No |
TRPC1 | Short transient receptor potential channel 1 | P48995 | Genetic | DIAPH1 | No |
CD2AP | CD2‐associated protein | Q9Y5K6 | Genetic | DIAPH1 | Yes |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Genetic | DIAPH1 | No |
TLN1 | Talin‐1 | Q9Y490 | Genetic | FYN | Yes |
SIAH1 | E3 Ub Ligase SIAH1 (seven in absentia homolog 1) | Q8IUQ4 | Genetic | FYN | No |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Physical | FYN | No |
TPM1 | Tropomyosin‐1 | P09493 | Genetic | PACS1 | Yes |
CTNNB1 | Beta Catenin | P35222 | Genetic | PACS1 | Yes |
FN1 | Fibronectin | P02751 | Genetic | PACS1 | Yes |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Genetic | PACS2 | No |
SIAH1 | E3 Ub Ligase SIAH1 (seven in absentia homolog 1) | Q8IUQ4 | Genetic | RGS7 | No |
CD2AP | CD2‐associated protein | Q9Y5K6 | Genetic | RGS7 | Yes |
FN1 | Fibronectin | P02751 | Genetic | RGS7 | Yes |
ABL1 | Abelson murine leukemia viral oncogene homolog 1 | P00519 | Genetic | RGS7 | No |
FN1 | Fibronectin | P02751 | Physical | TLN1 | Yes |
FN1 | Fibronectin | P02751 | Genetic | TLN1 | Yes |
TLN1 | Talin‐1 | Q9Y490 | Genetic | TPM1 | Yes |
FN1 | Fibronectin | P02751 | Genetic | TPM1 | Yes |
FYN | Tyrosine‐protein kinase Fyn | P06241 | Genetic | TRPC1 | No |
Discussion
The highly conserved exocyst complex is classically known for its role in targeting and docking vesicles, carrying proteins, from the trans‐Golgi network (TGN) to the cell membrane (Lipschutz and Mostov ). We previously showed that the exocyst is necessary for ciliogenesis (Zuo et al. ). However, if the exocyst was only trafficking vesicles carrying proteins necessary for ciliogenesis, one would expect to find it just at the base of the primary cilium; instead, we show here that exocyst Sec10, an essential component of the exocyst complex (Zuo et al. ), localizes not only to the base of primary cilia, but also all along the primary cilium and, indeed, in what appear to be cilia‐interacting exosomes (Fig. ). We also found that all eight members of the exocyst complex (Fig. ), as well as many regulatory GTPases (Fig. , Table ), are present in ELVs. Additionally, we show that fluorescently labeled exosomes appear to interact with renal cilia in living MDCK cells (Fig. , Movie S1). Lastly, we found that ELVs carry many known interactors of Smoothened (Fig. B, Table ), Polycystins 1 and 2, and Fibrocystin (Fig. C, Table ).
The exocyst has been shown to be regulated by many different small GTPases (Lipschutz and Mostov ) and to have other functions besides vesicle delivery (Lipschutz et al. ). The fact that the exocyst is found throughout the primary cilium suggests that it may have another role in the cilium besides simply trafficking vesicles carrying ciliary proteins from the TGN. The ciliary membrane is physically restricted from the adjacent cell membrane, and has a different protein and lipid composition than the adjacent cell membrane as well (Nachury et al. ). Therefore, one can imagine a scenario whereby the exocyst complex specifically targets ELVs containing ciliary proteins to the ciliary surface, or to multivesicular bodies (MVBs), for ELVs to be released into the extracellular environment, where they are subsequently taken up by primary cilia of the same or adjacent cells, and/or participate in ELV retrieval. This would be a logical mechanism to (Admyre et al. ) allow for the transfer of different membrane components to a physically restricted nascent ciliary membrane during ciliogenesis, to (Allen ) allow for the replenishment of various components of the ciliary membrane (including membrane proteins and, perhaps, different membrane lipids) in mature cilia, or (Bakeberg et al. ) to allow for intracellular (or intercellular) communication and signaling.
Further supporting a role other than simply targeting vesicles to the cilium, the entire exocyst, as well as many of its regulatory GTPases, are present in ELVs. This finding suggests that the exocyst complex is actively regulated within ELVs. Given that cells are highly efficient machines, we hypothesize that cells would not waste the energy required to target these proteins to ELVs if they were not serving a specific function within these vesicles. We propose that, in addition to being involved in targeting vesicles carrying proteins, the exocyst complex is centrally involved in regulating cilia/ELV interactions. Given the highly dynamic nature of cilia/exosome interactions observed in living cells (Fig. ), we think that cilia are equally likely to be involved in the uptake (as suggested above) and/or secretion of ELVs. The exocyst could play a role in either or both of these processes. For instance, the exocyst could help dock and unload critical cargo from ELVs to the primary cilium after ELVs have bound to the cilium. Additionally, perhaps in a similar fashion as it functions in the cell membrane, instead of being involved in facilitating cargo unloading to the cilium (or in addition to this role), once inside a primary cilium, the exocyst complex could help target specific cargo to ELVs at the tip of the cilium for secretion.
Importantly, there is experimental evidence from different model systems that argues in favor of primary cilia actively secreting ELVs. For example, recent work from Wood et al. () shows that the algae Chlamydomonas secretes bioactive, membrane‐bound vesicles from the distal ends of flagella, which are in many ways identical to cilia. In this case, the vesicles contain enzymes essential for budding. Although, one might be tempted to argue that this process could be limited to unicellular organisms, there is also experimental evidence of ciliary secretion in multicellular organisms. For example, as previously mentioned, Wang and colleagues recently demonstrated a role for extracellular vesicles carrying ciliary proteins in regulating mating behavior in C. elegans (Wang et al. ). Additionally, they showed that, in C. elegans, secretion of these vesicles does not take place via fusion of MVBs, but via vesicular budding at the ciliary base (Wang et al. ), thus providing an additional model system where the secretion of biologically active exosomes is associated with primary cilia. This leads to the hypothesis that these cilia‐associated mechanisms for secretion of bioactive exosomes are conserved in mammals.
Consistent with this hypothesis, hints of ciliary secretion in mammalian cells can be found in ciliary literature dating as far back as 1967 when The Renewal of Photoreceptor Outer Segments was first described (Young ). The outer segments (OS) of photoreceptor cells (which are, in fact, modified primary cilia) (Robertis ; Allen ), are renewed every 10 days (10% each day) by a process that involves the shedding of membrane‐bound discs/vesicles at the distal end of the photoreceptor/cilium (Sung and Chuang ). These vesicles are subsequently taken up and phagocytosed by the adjacent retinal pigment epithelial (RPE) cells (Young and Bok ; Bok and Hall ). Although this phenomenon was initially perceived as an eye‐specific process required for the maintenance of photoreceptor cells (Boesze‐Battaglia and Goldberg ; Sung and Chuang ), it clearly shows that at least some types of mammalian primary cilia secrete membrane‐bound vesicles from their distal ends, and, thus, suggests that secretion of exosomes by primary cilia is an evolutionarily conserved process maintained in mammals.
More recently, evidence suggests that cilia in other types of cells may also secrete membrane‐bound vesicles that mediate autocrine and paracrine signaling, and influence cellular (and likely bodily) functions. For example, Masyuk et al. () demonstrated that biliary exosomes interact with primary cilia in cholangiocytes, and that this interaction, in turn influenced the expression of an miRNA that regulates cholangiocyte proliferation, as well as played a key role in keeping the MAPK signaling pathway quiescent. There are, therefore, several examples, in addition to Chlamydomonas, where interactions between cilia and secreted membrane vesicles can regulate cellular function.
In summary, we show that (Admyre et al. ) the exocyst localizes along the length of the primary cilium (Zuo et al. ) and in vesicles that interact with the ciliary surface (Fig. , insets); (Allen ) that all eight known members of the exocyst complex (Fig. ) and (Bakeberg et al. ) most of its mammalian regulatory GTPases are found within ELVs (Fig. , Table ); (Barr and Sternberg ) that renal cells interact with vesicles tagged with a fluorescently labeled ciliary membrane protein in living cells (Fig. ), suggesting that cilia may be involved in the secretion and/or retrieval of ELVs; and that (Boesze‐Battaglia and Goldberg ;) ELVs carry a number of proteins known to interact with the ciliary proteins Smoothened, Polycystins 1 and 2 and Fibrocystin. These data, combined with the growing experimental evidence suggesting a biologically relevant role for cilia/ELV interactions, supports a model where the exocyst is centrally involved in the regulation of cilia/ELV interactions. The fact that the exocyst complex is required for normal ciliogenesis (Zuo et al. ), and that an exocyst mutation is the cause of the Joubert nephronophthisis form of PKD in a human family (Dixon‐Salazar et al. ), demonstrates the central role of the exocyst in regulating normal and pathogenic ciliogenesis, which now may also include cilia/ELV interactions.
Acknowledgments
The University of Pennsylvania Biomedical Imaging Core Facility of the Cancer Center is gratefully acknowledged for providing imaging services.
Conflict of Interest
None declared.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2014. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Cilia, organelles that function as cellular antennae, are central to the pathogenesis of “ciliopathies”, including various forms of polycystic kidney disease (
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Renal, Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
2 Renal Division, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina
3 Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas
4 Renal Division, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina; Department of Medicine, Ralph H. Johnson VAMC, Charleston, South Carolina